- Sarah A. Taylor1,
- Dorothy J. Giroux2,
- Kurt A. Jaeckle3,
- Timothy J. Panella4,
- Shaker R. Dakhil5 &
- …
- S. Clifford Schold6
38Accesses
10Citations
Abstract
Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.
This is a preview of subscription content,log in via an institution to check access.
Access this article
Subscribe and save
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime
Buy Now
Price includes VAT (Japan)
Instant access to the full article PDF.
Similar content being viewed by others
References
Annual Report to the Food and Drug Administration on Didemnin B (NSC-3253219, IND-245055), August 1996
Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of Didemnin B, a cyclic depsipeptide. J Cancer Clin Oncol 24: 1699–1706, 1988
Stewart JA, Low JB, Roberts JD, Blow A: A phase I clinical trial of Didemnin B. Cancer 68: 2550–2554, 1991
Author information
Authors and Affiliations
University of Kansas Medical Center, Kansas City, KS
Sarah A. Taylor
Southwest Oncology Group Statistical Center, Seattle, WA
Dorothy J. Giroux
University of Utah Medical Center, Salt Lake City, UT
Kurt A. Jaeckle
Thompson Cancer Survival Center, Knoxville, TN
Timothy J. Panella
Wichita CCOP, Wichita, KS
Shaker R. Dakhil
University of Texas Southwestern, Dallas, TX, USA
S. Clifford Schold
- Sarah A. Taylor
You can also search for this author inPubMed Google Scholar
- Dorothy J. Giroux
You can also search for this author inPubMed Google Scholar
- Kurt A. Jaeckle
You can also search for this author inPubMed Google Scholar
- Timothy J. Panella
You can also search for this author inPubMed Google Scholar
- Shaker R. Dakhil
You can also search for this author inPubMed Google Scholar
- S. Clifford Schold
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Taylor, S.A., Giroux, D.J., Jaeckle, K.A.et al. Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study.Invest New Drugs16, 331–332 (1998). https://doi.org/10.1023/A:1006273214056
Issue Date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative